Rigel Pharmaceuticals (RIGL) Return on Capital Employed (2011 - 2026)
Rigel Pharmaceuticals (RIGL) posted quarterly Return on Capital Employed of 29.69% for Q1 2026, down 1282.0% year-over-year from 2.51% in Q1 2025, and down 34.02% quarter-over-quarter from 45.0% in Q4 2025.
Rigel Pharmaceuticals (RIGL) Return on Capital Employed (2011 - 2026) Analysis & Trends
Rigel Pharmaceuticals' Return on Capital Employed history runs 16 years deep, the most recent figure standing at 29.69% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 1282.0% year-over-year to 29.69%; the TTM figure through Mar 2026 stood at 29.69% (down 1282.0% YoY), while the FY2025 annual figure was 52.38%, up 2108.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 29.69%, down from 45.0% in the prior quarter.
- The five-year high for Return on Capital Employed was 99.87% in Q2 2025, with the low at 106.05% in Q3 2022.
- The 5-year median for Return on Capital Employed is 30.0% (2023), against an average of 13.54%.
- The sharpest annual moves came in 2022 and 2025: Return on Capital Employed sank 9870 bps in 2022, then soared 11298 bps in 2025.
- Rigel Pharmaceuticals' Return on Capital Employed stood at 93.0% in 2022, then soared by 65 bps to 32.52% in 2023, then soared by 184 bps to 27.37% in 2024, then surged by 64 bps to 45.0% in 2025, then sank by 34 bps to 29.69% in 2026.
- Business Quant data shows RIGL's Return on Capital Employed at 29.69% in Q1 2026, 45.0% in Q4 2025, and 91.34% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Rigel Pharmaceuticals | 795.39 Mn | 700.06 Mn | 70.18 Mn | 20.86% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 20.86% |
| Mar 31, 2026 | 29.69% |
| Dec 31, 2025 | 45.00% |
| Sep 30, 2025 | 91.34% |
| Jun 30, 2025 | 99.87% |
| Mar 31, 2025 | 42.51% |
| Dec 31, 2024 | 27.37% |
| Sep 30, 2024 | 11.94% |
| Jun 30, 2024 | -13.10% |
| Mar 31, 2024 | -30.27% |
| Dec 31, 2023 | -32.52% |
| Sep 30, 2023 | -30.00% |
| Jun 30, 2023 | -44.96% |
| Mar 31, 2023 | -50.36% |
| Dec 31, 2022 | -93.00% |
| Sep 30, 2022 | -106.05% |
| Jun 30, 2022 | -96.23% |
| Mar 31, 2022 | -81.34% |
| Dec 31, 2021 | -11.02% |
| Sep 30, 2021 | -7.35% |